Australia’s Therapeutic Goods Administration is developing reforms to strengthen the evidence behind sunscreen SPF claims, including finished-product testing, laboratory oversight and ingredient quality. Its 27 October announcement describes work to be developed and introduced in stages—not a statement that every proposed requirement or label change is already in force. TGA reform announcement
The useful way to read the programme is as an evidence chain: what is tested, who performs the testing, how product quality is maintained and what claim reaches the label.
Testing the finished product is one part of the chain
The TGA’s detailed reform page identifies variability in SPF claims, reproducibility of testing methods and oversight of testing laboratories among the matters requiring improvement. A stated SPF and a dependable process for substantiating it are related but different things.
The agency plans to strengthen testing requirements, enable appropriate use of in-vitro or in-vivo methods, support laboratory accreditation and reference International Organization for Standardization standards directly in legislation. It also describes testing of the finished product and periodic testing while a product remains in the Australian Register of Therapeutic Goods. Testing reforms and stated implementation approach
These proposals address more than obtaining a single test report. They concern the methods, laboratories and continuing evidence used to support a claim. They do not, on their own, tell a reader the true SPF of a particular product or establish that every sunscreen has failed.
Ingredient quality and manufacturing have separate roles
The programme also includes developing quality requirements for specific ingredients and reviewing good manufacturing practice guidance. Those steps concern the consistency of what is made and the responsibilities around making it, rather than merely changing how a finished tube is advertised.
Separating these functions avoids treating one reform as a substitute for the others. A clearer claim cannot establish manufacturing consistency; a manufacturing requirement cannot replace evidence that supports the claim. The article describes how the TGA organizes those questions, rather than assessing any manufacturer’s compliance.
Our medical-device surveillance explainer covers a different jurisdiction and product regime, but illustrates a related distinction between maintaining evidence and reporting particular problems. Its rules should not be imported into Australian sunscreen regulation.
Cosmetic claims and later label review are different work
The TGA says it intends to improve consistency in the SPF limits that secondary, cosmetic sunscreens can claim, distinguishing them from products whose primary purpose is UV protection. It separately says further review and consultation on SPF labelling will take place later. Cosmetic-sunscreen and labelling distinctions
It would therefore be premature to announce that every current SPF label has been replaced, or to infer a final numerical cosmetic limit from the general reform announcement alone. The agency’s status statement says individual reforms will take time and may involve further consultation and legislative amendments.
The sequence matters to anyone briefing staff or planning product documentation: an announced direction, a published requirement and an implementation date are different records.
Consultation responses are evidence of participation, not unanimous support
The consultation ran from 26 March to 23 May 2026 and received 119 submissions, including from industry, laboratories, health professionals, consumers and other stakeholders. The consultation outcome links to the TGA’s response and proposed regulatory reforms. Consultation outcome
That count describes submissions, not 119 endorsements of every measure. Neither it nor the reform announcement supplies a new comparative test of named sunscreen brands.
The next developments to watch are the specific testing and quality requirements, their supporting guidance and their commencement arrangements. Those will determine how the announced evidence chain becomes an operating regulatory process.